Skip to main content
Premium Trial:

Request an Annual Quote

ITSI-Biosciences Gets $100K SBIR Grant

NEW YORK (GenomeWeb News) – ITSI-Biosciences has received a $100,000 Small Business Innovation Research grant from the National Cancer Institute to support the firm’s ongoing breast cancer biomarker program.
 
The Johnstown, Pa.-based firm is developing a biomarker-based blood test to detect and classify breast malignancies. The SBIR grant will support the development of a multiplexed assay using a suspended array technology and the development of a prototype breast disease classification, the firm said.
 
ITSI- Biosciences President and CSO Richard Somiari said in a statement that the firm’s test is “unique in its approach, because, it may allow detection and accurate classification of breast disease via a blood test; employing a reliable and sensitive RNA detection method that does not require RNA isolation and polymerase chain reaction.”

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.